Table 3.
Treatments 1 | Item 2 | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADA (U/L) |
AST (U/L) |
ALT (U/L) |
Apo B (ng/mL) |
LCAT (ng/mL) |
TCHOL (ng/mL) | PLTP (ng/mL) |
FCHOL (ng/mL) | G6PDH (mU/mL) | |
Day 21 | |||||||||
CON | 38.29 ± 3.47 | 155.31 ± 7.40 | 23.35 ± 2.76 | 91.24 ± 35.01 | 0.72 ± 0.01 | 11.99 ± 0.41 | 11.87 ± 3.60 | 136.31 ± 11.86 | 30.42 ± 0.71 |
MT | 55.39 ± 4.12 | 159.01 ± 15.09 | 19.86 ± 4.49 | 83.02 ± 9.58 | 0.53 ± 0.02 | 11.24 ± 0.51 | 13.38 ± 2.42 | 105.18 ± 16.54 | 28.81 ± 2.74 |
CON + 0.2% YCWE | 58.02 ± 4.00 | 167.53 ± 8.29 | 27.87 ± 11.22 | 84.57 ± 7.03 | 0.64 ± 0.03 | 14.25 ± 0.71 | 13.49 ± 0.80 | 83.38 ± 7.46 | 30.62 ± 0.57 |
MT + 0.2% YCWE | 42.75 ± 1.44 | 180.74 ± 24.08 | 23.8 ± 4.80 | 90.91 ± 9.46 | 0.67 ± 0.06 | 12.91 ± 1.12 | 15.28 ± 3.14 | 53.13 ± 12.62 | 33.9 ± 0.73 |
Treatment p-Values | |||||||||
Main effect | 0.009 | 0.664 | 0.864 | 0.984 | 0.052 | 0.093 | 0.849 | 0.009 | 0.186 |
Contrast p-Values | |||||||||
CON vs. MT | 0.008 | 0.868 | 0.720 | 0.768 | 0.010 | 0.497 | 0.704 | 0.117 | 0.469 |
CON vs. CON + 0.2% YCWE | 0.004 | 0.587 | 0.644 | 0.811 | 0.211 | 0.064 | 0.684 | 0.18 | 0.926 |
CON vs. MT + 0.2% YCWE | 0.385 | 0.273 | 0.962 | 0.990 | 0.410 | 0.408 | 0.399 | 0.002 | 0.138 |
MT vs. MT + 0.2% YCWE | 0.032 | 0.344 | 0.686 | 0.777 | 0.038 | 0.152 | 0.633 | 0.019 | 0.042 |
CON + 0.2% YCWE vs. MT + 0.2% YCWE | 0.014 | 0.557 | 0.677 | 0.820 | 0.637 | 0.239 | 0.652 | 0.127 | 0.159 |
Day 42 | |||||||||
CON | 27.62 ± 6.98 | 222.74 ± 14.23 | 10.46 ± 1.94 | 66.72 ± 7.11 | 0.77 ± 0.06 | 11.48 ± 1.03 | 2.38 ± 1.29 | 35.11 ± 6.46 | 29.74 ± 1.07 |
MT | 46.22 ± 12.54 | 227.06 ± 8.28 | 7.01 ± 2.39 | 95.49 ± 16.49 | 0.7 ± 0.04 | 11.44 ± 0.82 | 1.48 ± 0.59 | No data 3 | 28.6 ± 1.23 |
CON + 0.2% YCWE | 40.94 ± 7.55 | 242.74 ± 15.43 | 11.65 ± 2.22 | 73.61 ± 8.95 | 0.73 ± 0.09 | 9.74 ± 0.68 | 2.34 ± 0.78 | 91.14 ± 0.00 | 30.24 ± 0.70 |
MT + 0.2% YCWE | 50.39 ± 10.47 | 284.96 ± 42.74 | 7.2 ± 3.38 | 101.72 ± 13.57 | 0.67 ± 0.01 | 11.05 ± 0.18 | 1.87 ± 0.97 | No data | 28.89 ± 2.71 |
Treatment p-Values | |||||||||
Main effect | 0.422 | 0.317 | 0.509 | 0.203 | 0.709 | 0.378 | 0.893 | − | 0.881 |
Contrast p-Values | |||||||||
CON vs. MT | 0.210 | 0.903 | 0.366 | 0.132 | 0.451 | 0.973 | 0.521 | − | 0.631 |
CON vs. CON + 0.2% YCWE | 0.358 | 0.575 | 0.750 | 0.698 | 0.697 | 0.140 | 0.973 | − | 0.834 |
CON vs. MT + 0.2% YCWE | 0.134 | 0.106 | 0.392 | 0.075 | 0.293 | 0.694 | 0.714 | − | 0.719 |
MT vs. MT + 0.2% YCWE | 0.768 | 0.129 | 0.959 | 0.726 | 0.748 | 0.718 | 0.779 | − | 0.903 |
CON + 0.2% YCWE vs. MT + 0.2% YCWE | 0.509 | 0.252 | 0.252 | 0.140 | 0.491 | 0.254 | 0.739 | − | 0.572 |
1 ADA: adenosine deaminase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Apo B: apolipoprotein B; LCAT: lecithin cholesterol acyltransferase; TCHOL: total cholesterol; PLTP: plasma phospholipid-transfer protein; FCHOL: free cholesterol; G6PDH: glucose 6-phosphate dehydrogenase; 2 CON: control diet without mycotoxins; MT: diet containing mycotoxin DDGS; CON + 0.2% YCWE; NC + 0.2% YCWE; 3 No data: readings were out of range causing data to be unavailable.